References
- Uchida Y, Takada K, Tsugu Y, Ueda M, Yamashita T, Ando Y, Kobayashi S, et al. Two brothers homozygous for the TTR V30M both presenting with a phenotype dominated by central nervous complications. Amyloid 2015;22:261–2.
- Kon T, Misumi Y, Nishijima H, Honda M, Suzuki C, Baba M, Inomata Y, et al. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report. Amyloid 2015;22:203–4.
- Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78:637–43.
- Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015;99:1847–54.
- Suhr OB, Larsson M, Ericzon BG, Wilczek HE, FAPWTR's investigators. Survival after transplantation in patients with mutations other than Val30Met: Extracts from the FAP World Transplant Registry. Transplantation 2016;100:373–81
- Okumura K, Yamashita T, Masuda T, Misumi Y, Ueda A, Ueda M, Obayashi K, et al. Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation. Amyloid 2016;23:39–45.
- Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92.
- Yanagisawa A, Ueda M, Sueyoshi T, Nakamura E, Tasaki M, Suenaga G, Motokawa H, et al. Knee osteoarthritis associated with different kinds of amyloid deposits and the impact of aging on type of amyloid. Amyloid 2016;23:26–32.